Eton Pharmaceuticals FY2026 Revenue expected to be more than $145.000M vs $121.326M Est

Benzinga Newsdesk www.benzinga.com Positive 72.7%

Neg 0% Neu 0% Pos 72.7%

Eton Pharmaceuticals (NASDAQ:ETON) FY2026 Revenue expected to be more than $145.000M vs $121.326M Est

Comments

No comments yet. Be the first!